-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Peer-reviewed/randomized controlled trials/person
The study included 146 peanut-allergic children and measured desensitization (safe intake of 5,000 mg of peanut protein powder in a food challenge following a two-and-a-half-year daily treatment period under the supervision of the investigator) and remission (26 after treatment ended).
Among the children receiving oral peanut immunotherapy, 71% (68/96) achieved desensitization compared with 2% (1/50) of the placebo group and 21% (20/96) of the placebo group achieved remission, and The placebo group was 2% (1/50)
Further analysis showed that younger children were more likely to achieve remission than older children at the start of treatment
In this trial, children were closely supervised and given small amounts of peanut protein powder, which was gradually increased to 2,000 mg per day (equivalent to 6 peanuts)
article title
Efficacy and safety of oral immunotherapy in children aged 1–3 years with peanut allergy (the Immune Tolerance Network IMPACT trial): a randomised placebo-controlled study
